We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Post-Treatment PSA Level May Predict RT Outcomes

By HospiMedica International staff writers
Posted on 14 Jun 2018
Prostate-specific antigen (PSA) levels three months after radiotherapy (RT) are strong markers of prostate cancer outcomes, according to a new study.

Researchers at the University of California, San Diego (UCSD, USA) and Dana-Farber Cancer Institute (Boston, MA, USA) conducted a study involving 5,783 patients with intermediate-risk or high-risk localized prostate cancer diagnosed in the years 2000-2015 and treated with RT and androgen deprivation therapy. More...
The aim of the study was to examine the association between three-month post-RT PSA level and biochemical progression-free survival (bPFS), prostate cancer-specific survival (PCSS), and overall survival (OS).

In all, there were 2,651 patients with intermediate-risk and 3,132 with high-risk disease, with about 11% harboring a three-month PSA level higher than 0.50 ng/mL, which was found to be strongly associated with each outcome, as compared to patients with a three-month PSA value lower than 0.10 ng/mL. When the groups were analyzed separately, three-month PSA level was found to be predictive of OS in the high-risk group, but not in the intermediate-risk group. The study was published on May 4, 2018, in Cancer.

“The three month post‐RT PSA level appears to be a strong prognostic biomarker for bPFS, PCSS, and OS in patients with intermediate‐risk and high‐risk prostate cancer, particularly those with high‐risk disease,” concluded lead author Alex Bryant, BSc, of the UCSD department of radiation medicine and applied sciences, and colleagues. “The three month PSA measurement may augment clinical decision making and holds promise as a potential surrogate endpoint in clinical trials.”

PSA is a glycoprotein enzyme secreted by the epithelial cells of the prostate gland, and is encoded in humans by the kallikrein-3 (KLK3) gene. PSA is produced for the ejaculate, where it liquefies semen in the seminal coagulum, allowing sperm to swim freely; it is also believed to be involved in dissolving cervical mucus, allowing the entry of sperm into the uterus. PSA is present in small quantities in the serum of men with healthy prostates, but is elevated in the presence of prostate cancer, prostatitis or benign prostatic hyperplasia (BPH).

Related Links:
University of California, San Diego
Dana-Farber Cancer Institute

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Radiofrequency Generator
GX1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: A view inside the custom virtual reality environment used in the study: a calm room with a teddy bear, soft colors and large windows looking out over the sea. (Image Credit: Walaa S. Abu Rukbah et al., Virginia Commonwealth University; CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

Virtual Reality Program May Reduce Anxiety Before Pediatric Surgery

Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more

Point of Care

view channel
Image: Jessica Ramella-Roman, professor of biomedical engineering at Florida International University, holding the PPRIM (Portable Preterm Imaging) device designed to detect early signs of preterm labor risk. (Photo courtesy of Florida International University)

Handheld Imaging Device May Help Identify Preterm Birth Risk Earlier

Preterm birth, defined as delivery before 37 weeks of pregnancy, can lead to serious neonatal complications, including neurological, developmental, and respiratory problems. However, identifying pregnancies... Read more

Business

view channel
Image: Stryker has acquired ZuriMED, adding the FiberLocker System, a rotator cuff augmentation technology designed to strengthen repairs, to its Sports Medicine portfolio. (Photo courtesy of ZuriMED)

Stryker Completes Acquisition to Broaden Shoulder Surgery Offerings

Stryker (Portage, MI, USA) has completed its acquisition of ZuriMED (Zurich, Switzerland), a privately held developer of the FiberLocker System, expanding its Sports Medicine portfolio with a commercialized... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.